Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 16 | 2023 | 98 | 1.970 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 13 | 2023 | 24 | 1.520 |
Why?
|
| Immunosuppressive Agents | 12 | 2023 | 130 | 0.890 |
Why?
|
| Natalizumab | 3 | 2019 | 21 | 0.680 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2020 | 88 | 0.660 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2019 | 113 | 0.650 |
Why?
|
| Immunologic Factors | 2 | 2019 | 33 | 0.650 |
Why?
|
| Filgrastim | 1 | 2019 | 5 | 0.640 |
Why?
|
| JC Virus | 1 | 2019 | 98 | 0.580 |
Why?
|
| Immunoglobulin G | 6 | 2020 | 92 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2009 | 59 | 0.320 |
Why?
|
| Disease Progression | 4 | 2020 | 676 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2019 | 1069 | 0.290 |
Why?
|
| Interferon Regulatory Factor-1 | 3 | 2011 | 10 | 0.270 |
Why?
|
| Adult | 22 | 2020 | 7516 | 0.260 |
Why?
|
| Aquaporin 4 | 2 | 2014 | 6 | 0.220 |
Why?
|
| Neuromyelitis Optica | 2 | 2014 | 7 | 0.220 |
Why?
|
| Female | 24 | 2020 | 14520 | 0.210 |
Why?
|
| Humans | 31 | 2023 | 26260 | 0.210 |
Why?
|
| Central Nervous System Diseases | 1 | 2023 | 15 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 189 | 0.200 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 3 | 2011 | 55 | 0.190 |
Why?
|
| Male | 18 | 2020 | 14168 | 0.190 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2020 | 7 | 0.170 |
Why?
|
| Middle Aged | 19 | 2016 | 8541 | 0.170 |
Why?
|
| Gadolinium | 2 | 2016 | 9 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2023 | 3285 | 0.150 |
Why?
|
| Double-Blind Method | 6 | 2016 | 411 | 0.140 |
Why?
|
| Brain | 3 | 2019 | 1603 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2023 | 3283 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 13 | 0.130 |
Why?
|
| 4-Aminopyridine | 2 | 1991 | 3 | 0.120 |
Why?
|
| Transplantation Conditioning | 3 | 2006 | 19 | 0.120 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 12 | 0.120 |
Why?
|
| Muscular Diseases | 1 | 2014 | 16 | 0.120 |
Why?
|
| Quality of Life | 2 | 2013 | 606 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 1722 | 0.110 |
Why?
|
| Cladribine | 2 | 2023 | 2 | 0.110 |
Why?
|
| Tablets | 2 | 2023 | 5 | 0.110 |
Why?
|
| Decompression, Surgical | 1 | 2014 | 93 | 0.110 |
Why?
|
| Central Nervous System | 3 | 2023 | 55 | 0.100 |
Why?
|
| Aquaporins | 1 | 2012 | 5 | 0.100 |
Why?
|
| Escherichia coli Proteins | 1 | 2012 | 9 | 0.100 |
Why?
|
| Autoimmune Diseases | 2 | 2006 | 48 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 2011 | 13 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 41 | 0.090 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 247 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2011 | 7 | 0.090 |
Why?
|
| Oligodendroglia | 1 | 2011 | 35 | 0.090 |
Why?
|
| Neuroglia | 1 | 2011 | 49 | 0.090 |
Why?
|
| Young Adult | 5 | 2020 | 1948 | 0.090 |
Why?
|
| Disability Evaluation | 3 | 2009 | 234 | 0.080 |
Why?
|
| DNA | 1 | 2010 | 104 | 0.080 |
Why?
|
| Recurrence | 2 | 2023 | 288 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 8 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 53 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2011 | 417 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 161 | 0.080 |
Why?
|
| Animals | 6 | 2012 | 3551 | 0.070 |
Why?
|
| Mice | 4 | 2012 | 1380 | 0.070 |
Why?
|
| Injections, Subcutaneous | 2 | 2016 | 25 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 330 | 0.060 |
Why?
|
| Europe | 2 | 2014 | 57 | 0.050 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 2 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 193 | 0.050 |
Why?
|
| Adolescent | 3 | 2013 | 2172 | 0.050 |
Why?
|
| Rabbits | 2 | 2012 | 181 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 114 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 505 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1347 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2011 | 298 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1295 | 0.040 |
Why?
|
| Astrocytoma | 1 | 1999 | 15 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1999 | 15 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 420 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 1999 | 105 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 163 | 0.040 |
Why?
|
| Spinal Cord | 1 | 1999 | 72 | 0.040 |
Why?
|
| Transplantation, Autologous | 3 | 2009 | 159 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 1801 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 82 | 0.040 |
Why?
|
| Nasopharyngitis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2016 | 8 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 15 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 40 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 25 | 0.030 |
Why?
|
| Whole-Body Irradiation | 3 | 2003 | 10 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 31 | 0.030 |
Why?
|
| Muscle Fatigue | 1 | 1996 | 12 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 62 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 45 | 0.030 |
Why?
|
| Pneumonia | 1 | 2016 | 72 | 0.030 |
Why?
|
| Fatigue | 1 | 1996 | 60 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2003 | 294 | 0.030 |
Why?
|
| Antilymphocyte Serum | 2 | 2009 | 4 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2014 | 20 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2010 | 138 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 683 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 160 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 154 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2012 | 4 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2012 | 11 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 189 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2012 | 59 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 146 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 185 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 8595 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 204 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1996 | 1034 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2011 | 6 | 0.020 |
Why?
|
| Placebos | 1 | 1991 | 67 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 134 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 56 | 0.020 |
Why?
|
| Movement | 1 | 1991 | 112 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 216 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 592 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2010 | 14 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 349 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 70 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 19 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 48 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 59 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 57 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2010 | 38 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2010 | 57 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 93 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 73 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 264 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 85 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 4 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 116 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 13 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 60 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 166 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 422 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1998 | 8 | 0.020 |
Why?
|
| Antigens, CD34 | 2 | 1998 | 14 | 0.020 |
Why?
|
| Methylprednisolone | 2 | 1998 | 19 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 473 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 247 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 600 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2014 | 376 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 397 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 556 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 853 | 0.020 |
Why?
|
| Factor VIII | 1 | 2006 | 32 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2003 | 158 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 1999 | 18 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 1999 | 40 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1998 | 5 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1998 | 13 | 0.010 |
Why?
|
| Torque | 1 | 1996 | 24 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1998 | 173 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1996 | 48 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1998 | 571 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1996 | 567 | 0.010 |
Why?
|
| Vision Disorders | 1 | 1990 | 20 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1990 | 105 | 0.010 |
Why?
|
| Reaction Time | 1 | 1990 | 100 | 0.010 |
Why?
|